Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

To join this study, participants needed to be at least 18 years old and have a specific type of high-risk, early-stage bladder cancer that hasn't spread into the muscle. Importantly, they must not have had BCG treatment for this cancer before. The doctors also needed to confirm the cancer diagnosis from tissue collected during surgery.

Before taking part, participants would have had scans (like CT or MRI) to make sure the cancer hadn't spread to other parts of their body. They also needed to be generally well, meaning they could carry out most daily activities without too much difficulty. Their blood pressure needed to be within a healthy range, and routine blood tests (checking blood counts and organ function) had to show healthy results.

For some patients, a second operation to remove the tumor might have been needed before they could join, to make sure all visible cancer was removed and to confirm the diagnosis. If you meet these general criteria, your doctor could then check the more detailed requirements.

If you were eligible and chose to take part in this study, you would have been randomly assigned to one of two treatment groups: either receiving BCG alone or receiving BCG plus atezolizumab. This means a computer decides which treatment you get, much like flipping a coin, to ensure fairness.

Both treatments involve a course of medication. You would have had regular appointments at the hospital for these treatments and to have various check-ups. These check-ups would involve physical examinations, blood tests, and possibly scans to monitor your health and how the treatment is working. Doctors would also carefully check for any side effects.

The study would involve regular follow-up over a period of time to track your progress and see how long you remain free from cancer returning. The total duration of active treatment and follow-up would be explained in detail by your medical team.